Eisaku Morimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eisaku Morimoto has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Katayama
Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Okayama, Japan
1 shared publication - Erika Sasaki
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Okayama, 700-8558 , Japan
1 shared publication - Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
1 shared publication Katsuhiko Tada
Department of Obstetrics and Gynecology, NHO Okayama Medical Center, Okayama, Okayama Prefecture, Japan
1 shared publication- Kazumasa Kumazawa
Department of Obstetrics and Gynecology, NHO Okayama Medical Center, Okayama, Okayama Prefecture, Japan
1 shared publication - Kazuyuki Hida
Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Okayama, Japan
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005114
Perinatal and postpartum insulin secretion capacity in women with early-onset and late-onset gestational diabetes
Introduction: Gestational diabetes mellitus (GDM) is associated with metabolic risks and adverse maternal and fetal perinatal outcomes. This study aimed to compare pregnancy outcomes, postpartum glucose intolerance and insulin secretion capacity in women with early-onset GDM (EGDM, diagnosed<24 weeks) and late GDM (LGDM, diagnosed≥24 weeks) in Japan. Research design and methods: This single-center, retrospective study included 107 women with EGDM and 109 with LGDM. GDM was diagnosed through the 75 g oral glucose tolerance test. Postpartum glucose tolerance was assessed 4–16 weeks post partum. Maternal and neonatal outcomes, insulin secretion, and postpartum glucose tolerance were analyzed and compared. Subgroup analyses were performed for women with and without obesity. Results: Although gestational weight gain was significantly lower in women with EGDM than in those with LGDM, pregnancy outcomes, including neonatal birth weight, small for gestational age and large for gestational age, were comparable between the two groups. However, postpartum glucose intolerance was more prevalent in women with EGDM, particularly in those without obesity who also had significantly lower initial insulin secretion capacity. Insulin resistance was comparable between the groups, suggesting that reduced insulin secretion, rather than insulin resistance, contributes to postpartum glucose intolerance in EGDM. Conclusions: EGDM in women without obesity is associated with a high risk for postpartum glucose intolerance. This could be related to impaired insulin secretion rather than insulin resistance. These findings highlight the need for close monitoring and tailored interventions for patients with EGDM. More research is required to improve diagnostic and management strategies, considering ethnic variations in insulin secretion and glucose tolerance.
- 1 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005114
Open AccessPerinatal and postpartum insulin secretion capacity in women with early-onset and late-onset gestational diabetes
Introduction: Gestational diabetes mellitus (GDM) is associated with metabolic risks and adverse maternal and fetal perinatal outcomes. This study aimed to compare pregnancy outcomes, postpartum glucose intolerance and insulin secretion capacity in women with early-onset GDM (EGDM, diagnosed<24 weeks) and late GDM (LGDM, diagnosed≥24 weeks) in Japan. Research design and methods: This single-center, retrospective study included 107 women with EGDM and 109 with LGDM. GDM was diagnosed through the 75 g oral glucose tolerance test. Postpartum glucose tolerance was assessed 4–16 weeks post partum. Maternal and neonatal outcomes, insulin secretion, and postpartum glucose tolerance were analyzed and compared. Subgroup analyses were performed for women with and without obesity. Results: Although gestational weight gain was significantly lower in women with EGDM than in those with LGDM, pregnancy outcomes, including neonatal birth weight, small for gestational age and large for gestational age, were comparable between the two groups. However, postpartum glucose intolerance was more prevalent in women with EGDM, particularly in those without obesity who also had significantly lower initial insulin secretion capacity. Insulin resistance was comparable between the groups, suggesting that reduced insulin secretion, rather than insulin resistance, contributes to postpartum glucose intolerance in EGDM. Conclusions: EGDM in women without obesity is associated with a high risk for postpartum glucose intolerance. This could be related to impaired insulin secretion rather than insulin resistance. These findings highlight the need for close monitoring and tailored interventions for patients with EGDM. More research is required to improve diagnostic and management strategies, considering ethnic variations in insulin secretion and glucose tolerance.
- Open Access
- 5 August 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (10) , bvac121
Effects of Wnt-β-Catenin Signaling and Sclerostin on the Phenotypes of Rat Pheochromocytoma PC12 Cells
Pheochromocytomas and paragangliomas (PPGLs) are classified into 3 major categories with distinct driver genes: pseudohypoxia, kinase signaling, and Wnt-altered subtypes. PPGLs in the Wnt-altered subtype are sporadic and tend to be aggressive with metastasis, where somatic gene fusions affecting mastermind-like 3 (MAML3) and somatic mutations in cold shock domain containing E1 (CSDE1) cause overactivation of Wnt-β-catenin signaling. However, the relation between Wnt-β-catenin signaling and the biological behavior of PPGLs remains unexplored. In rat pheochromocytoma PC12 cells, Wnt3a treatment enhanced cell proliferation and suppressed mRNA expression of tyrosine hydroxylase (TH), the rate-limiting enzyme of catecholamine biosynthesis, and dopamine secretion. We identified the expression of sclerostin in PC12 cells, which is known as an osteocyte-derived negative regulator for Wnt signaling-driven bone formation. Inhibition of endogenous Wnt pathway by XAV939 or sclerostin resulted in attenuated cell proliferation and increased TH expression. Furthermore, Wnt3a pretreatment suppressed bone morphogenetic protein (BMP)-induced Smad1/5/9 phosphorylation whereas BMPs enhanced sclerostin expression in PC12 cells. In the Wnt-altered subtype, the increased Wnt-β-catenin pathway may contribute the aggressive clinical behavior with reduced catecholamine production. Furthermore, upregulated expression of sclerostin by BMPs may explain the osteolytic metastatic lesions observed in metastatic PPGLs.
- 5 August 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (10) , bvac121
Open AccessEffects of Wnt-β-Catenin Signaling and Sclerostin on the Phenotypes of Rat Pheochromocytoma PC12 Cells
Pheochromocytomas and paragangliomas (PPGLs) are classified into 3 major categories with distinct driver genes: pseudohypoxia, kinase signaling, and Wnt-altered subtypes. PPGLs in the Wnt-altered subtype are sporadic and tend to be aggressive with metastasis, where somatic gene fusions affecting mastermind-like 3 (MAML3) and somatic mutations in cold shock domain containing E1 (CSDE1) cause overactivation of Wnt-β-catenin signaling. However, the relation between Wnt-β-catenin signaling and the biological behavior of PPGLs remains unexplored. In rat pheochromocytoma PC12 cells, Wnt3a treatment enhanced cell proliferation and suppressed mRNA expression of tyrosine hydroxylase (TH), the rate-limiting enzyme of catecholamine biosynthesis, and dopamine secretion. We identified the expression of sclerostin in PC12 cells, which is known as an osteocyte-derived negative regulator for Wnt signaling-driven bone formation. Inhibition of endogenous Wnt pathway by XAV939 or sclerostin resulted in attenuated cell proliferation and increased TH expression. Furthermore, Wnt3a pretreatment suppressed bone morphogenetic protein (BMP)-induced Smad1/5/9 phosphorylation whereas BMPs enhanced sclerostin expression in PC12 cells. In the Wnt-altered subtype, the increased Wnt-β-catenin pathway may contribute the aggressive clinical behavior with reduced catecholamine production. Furthermore, upregulated expression of sclerostin by BMPs may explain the osteolytic metastatic lesions observed in metastatic PPGLs.